DJIA 17,279.74 13.75 0.08%
NASDAQ 4,579.79 -13.64 -0.30%
S&P 500 2,010.40 -0.96 -0.05%
market minute promo

Emergent BioSolutions (NYSE: EBS)

21.80 -0.40 (-1.80%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

EBS $21.80 -1.80%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $22.24
Previous Close $22.20
Daily Range $21.62 - $22.47
52-Week Range $17.31 - $28.48
Market Cap $817.0M
P/E Ratio 60.00
Dividend (Yield) $0.00 (0.0%)
Volume 438,185
Average Daily Volume 205,319
Current FY EPS $0.66

Sector

Healthcare

Industry

Drugs

Emergent BioSolutions (EBS) Description

Emergent BioSolutions makes the only FDA-approved anthrax vaccine. Website: http://www.emergentbiosolutions.com/

News & Commentary Rss Feed

You Shouldn't Ignore Gilead's Idelalisib

Gilead Sciences is widely known for its HIV drug portfolio and for its high-profile hep-C drug sofosbuvir. But it also has a potential winner with idelalisib, a blood cancer drug with a promising future.

Emergent BioSolutions Wins $29M Anthrax Vaccine Deal - Analyst Blog

Emergent BioSolutions Awarded $29M 5-Year Contract To Develop A Dry Formulation Of NuThrax, A Next G

Emergent BioSolutions Awarded $29M 5-Year Contract To Develop A Dry Formulation Of NuThrax, A Next Generation Anthrax Vaccine

Emergent BioSolutions, MorphoSys Tie Up on Cancer Candidate - Analyst Blog

MorphoSys And Emergent BioSolutions Sign License Agreement to Co-Develop And Commercialize Prostate

MorphoSys And Emergent BioSolutions Sign License Agreement to Co-Develop And Commercialize Prostate Cancer Drug Candidate ES414

Emergent BioSolutions, Inc. (EBS): New Analyst Report from Zacks Equity Research - Zacks Equity Rese

Emergent BioSolutions, Inc. (EBS): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

Emergent BioSolutions Misses on Earnings, Ups Revenue View - Analyst Blog

Emergent BioSolutions' (EBS) CEO Dan Abdun-Nabi on Q2 2014 Results - Earnings Call Transcript

Emergent BioSolutions (EBS) Q2 2014 Results - Earnings Call Webcast

Will Emergent BioSolutions (EBS) Earnings Disappoint in Q2? - Analyst Blog

Biodel Q2 Loss Wider Than Expected - Analyst Blog

See More EBS News...

EBS's Top Competitors

EBS $21.80 (-1.80%)
Current stock: EBS
AMGN $144.01 (1.40%)
Current stock: AMGN
GILD $105.96 (0.03%)
Current stock: GILD
BIIB $329.24 (-0.23%)
Current stock: BIIB